**Anuh Pharma Stock Downgraded to ‘Sell’ by MarketsMOJO**
Anuh Pharma, a small-cap player in the pharmaceuticals and drugs industry, has received a downgrade to ‘Sell’ from MarketsMOJO as of December 13, 2024. This decision follows a report of flat results for the company in September 2024, alongside a notable decline in operating cash flow, which reached its lowest at Rs 12.93 crore. The debt-to-equity ratio remains low at 0 times, indicating a manageable debt level.
The stock is currently categorized within a mildly bearish range, with technical indicators such as MACD, KST, DOW, and OBV reflecting a deteriorating trend since mid-December. Despite the company’s attractive return on equity (ROE) of 19.5 and a price-to-book value of 3.6, domestic mutual funds hold no stake in Anuh Pharma, suggesting potential concerns regarding its valuation or business outlook.
Over the past year, Anuh Pharma has generated a return of 46.05%, with profits increasing by 32.6%. The company’s PEG ratio stands at 0.6, indicating a market-beating performance in both the long and near term.
